FOLD Logo

Amicus Therapeutics, Inc. (FOLD) 

NASDAQ
Market Cap
$3.34B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
544 of 776
Rank in Industry
293 of 433

Largest Insider Buys in Sector

FOLD Stock Price History Chart

FOLD Stock Performance

About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate …

Insider Activity of Amicus Therapeutics, Inc.

Over the last 12 months, insiders at Amicus Therapeutics, Inc. have bought $0 and sold $7.19M worth of Amicus Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Amicus Therapeutics, Inc. have bought $359,521 and sold $13.19M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,500 shares for transaction amount of $15,735 was made by WHITMAN BURKE W (director) on 2021‑11‑01.

List of Insider Buy and Sell Transactions, Amicus Therapeutics, Inc.

2024-11-01SalePresident and CEO
7,500
0.0025%
$11.46$85,960-1.22%
2024-10-01SalePresident and CEO
7,500
0.0025%
$10.60$79,493-0.66%
2024-09-03SalePresident and CEO
7,500
0.0025%
$11.71$87,798-3.70%
2024-08-01SalePresident and CEO
7,500
0.0026%
$10.34$77,519+10.69%
2024-07-05SalePresident and CEO
6,100
0.0021%
$10.00$61,0290.00%
2024-07-01SalePresident and CEO
1,400
0.0005%
$10.00$14,0030.00%
2024-06-03SalePresident and CEO
7,500
0.0025%
$10.00$75,000+5.91%
2024-05-01SalePresident and CEO
7,500
0.0024%
$10.07$75,524+0.14%
2024-04-01SalePresident and CEO
7,500
0.0025%
$11.67$87,496-10.21%
2024-03-05Saledirector
7,500
0.0025%
$13.40$100,500-20.16%
2024-03-04Saledirector
7,500
0.0025%
$13.29$99,675-20.88%
2024-03-01SalePresident and CEO
15,833
0.0053%
$13.14$208,017-19.83%
2024-03-01SaleExecutive Chairman
29,181
0.01%
$13.35$389,543-19.83%
2024-02-15SalePresident and CEO
4,167
0.0015%
$14.00$58,338-23.54%
2024-02-15SaleExecutive Chairman
31,614
0.0113%
$13.81$436,551-23.54%
2024-02-15SaleChief People Officer
4,427
0.0016%
$14.00$61,978-23.54%
2024-02-07SaleChief Legal Officer
29,600
0.0104%
$13.00$384,818-16.35%
2024-02-06SaleChief Legal Officer
400
0.0001%
$13.00$5,200-15.95%
2024-02-01SalePresident and CEO
15,833
0.0054%
$12.56$198,858-12.94%
2024-02-01SaleExecutive Chairman
31,614
0.0107%
$12.62$398,918-12.94%

Insider Historical Profitability

8.2%
Campbell Bradley LPresident and CEO
886654
0.2989%
$11.28378+51.18%
Crowley John FExecutive Chairman
573478
0.1934%
$11.285162<0.0001%
Rosenberg EllenChief Legal Officer
367654
0.124%
$11.28112<0.0001%
Castelli JeffChief Development Officer
340661
0.1149%
$11.28312
MCGLYNN MARGARET Gdirector
59289
0.02%
$11.2818<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$332.25M9.5228.2M-1.01%-$3.39M0.01
Perceptive Advisors$330.52M9.4728.06M0%+$00.21
Avoro Capital Advisors Llc$322.77M9.2527.4M0%+$03.87
BlackRock$269.17M7.7122.85M-0.6%-$1.63M0.01
Wellington Management Company$221.51M6.3518.8M+23.79%+$42.57M0.04
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.